[go: up one dir, main page]

BR9911389A - Composição de peptìdio como imunógeno para o tratamento de alergia - Google Patents

Composição de peptìdio como imunógeno para o tratamento de alergia

Info

Publication number
BR9911389A
BR9911389A BR9911389-9A BR9911389A BR9911389A BR 9911389 A BR9911389 A BR 9911389A BR 9911389 A BR9911389 A BR 9911389A BR 9911389 A BR9911389 A BR 9911389A
Authority
BR
Brazil
Prior art keywords
ige
peptides
immunogen
allergy
treatment
Prior art date
Application number
BR9911389-9A
Other languages
English (en)
Other versions
BRPI9911389B8 (pt
BRPI9911389B1 (pt
Inventor
Chang Yi Wang
Alan M Walfield
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of BR9911389A publication Critical patent/BR9911389A/pt
Publication of BRPI9911389B1 publication Critical patent/BRPI9911389B1/pt
Publication of BRPI9911389B8 publication Critical patent/BRPI9911389B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçãO DE PEPTìDIO COMO IMUNóGENO PARA O TRATAMENTO DE ALERGIA"<D>. A presente invenção apresenta peptídios que compeendem uma seq³ência homóloga a uma porção do terceiro domínio constante da cadeia pesada epsílon da IgE, covalentemente ligada ou a (1) uma proteína carreadora, ou a (2) um epítopo de célula auxiliar T e, opcionalmente, também a outras seq³ências imunoestimuladoras. A presente invenção apresenta o uso de tais peptídios como imunógenos para acarretar a produção em mamíferos de anticorpos policlonais de elevada titulação, os quais são específicos para um sítio de efetor alvo na cadeia pesada epsílon de IgE. Os peptídios devem ser úteis em composições farmacêuticas, para que se obtenha uma imunoterapia para doenças alérgicas mediadas por IgE.
BRPI9911389A 1998-06-20 1999-06-21 peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo BRPI9911389B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10028798A 1998-06-20 1998-06-20
US09/100,287 1998-06-20
PCT/US1999/013959 WO1999067293A1 (en) 1998-06-20 1999-06-21 Peptide composition as immunogen for the treatment of allergy

Publications (3)

Publication Number Publication Date
BR9911389A true BR9911389A (pt) 2001-03-20
BRPI9911389B1 BRPI9911389B1 (pt) 2018-03-20
BRPI9911389B8 BRPI9911389B8 (pt) 2021-05-25

Family

ID=22279023

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9911389A BRPI9911389B8 (pt) 1998-06-20 1999-06-21 peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo

Country Status (13)

Country Link
US (2) US6811782B1 (pt)
EP (1) EP1090039B1 (pt)
JP (1) JP4031201B2 (pt)
CN (1) CN1259340C (pt)
AT (1) ATE429448T1 (pt)
AU (1) AU757919B2 (pt)
BR (1) BRPI9911389B8 (pt)
CA (1) CA2329754C (pt)
DE (1) DE69940775D1 (pt)
DK (1) DK1090039T3 (pt)
TW (1) TWI227241B (pt)
WO (1) WO1999067293A1 (pt)
ZA (1) ZA200006384B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
RU2245163C2 (ru) 1998-11-30 2005-01-27 Сайтос Байотекнолэджи АГ Композиция (варианты), способ получения не природной упорядоченной и содержащей повторы антигенной матрицы, способ терапевтического лечения и способ иммунизации
MXPA01008612A (es) * 1999-02-25 2003-06-24 Smithkline Beecham Biolog Epitopos o mimotopos derivados de los dominos c-epsilon-3 o c-epsilon-4 de ige, antagonistas de los mismos y sus usos terapeuticos.
AU778551B2 (en) * 2000-01-14 2004-12-09 Daiichi Pharmaceutical Co., Ltd. Novel peptide and screening method by using the same
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
GB0020717D0 (en) * 2000-08-22 2000-10-11 Smithkline Beecham Biolog Novel compounds and process
EP1967206B1 (en) 2000-08-30 2012-10-10 Pfizer Products Inc. Anti-IgE vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2002092773A2 (en) * 2001-05-15 2002-11-21 Ortho-Mcneil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
RU2004135541A (ru) * 2002-06-11 2005-10-10 ГлаксоСмитКлайн Байолоджикалз с.а. (BE) Иммуногенные композиции
US20060052592A1 (en) 2002-06-20 2006-03-09 Levinson Arnold I Vaccines for suppressing ige-mediated allergic disease and methods for using the same
CN102061288A (zh) 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
EP1523334A2 (en) 2002-07-18 2005-04-20 Cytos Biotechnology AG Hapten-carrier conjugates and uses thereof
AU2003250110C1 (en) 2002-07-19 2008-05-29 Novartis Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
PL1709073T3 (pl) * 2003-11-26 2012-01-31 Max Planck Gesellschaft Substancja wiążąca receptor IIb Fc ludzkiej IgG (FcγRIIb)
CN102702359A (zh) * 2004-02-02 2012-10-03 泰勒公司 新的IgE表位的鉴别
US8080249B2 (en) * 2005-06-30 2011-12-20 Risk Glifford G Methods to treating chronic obstructive pulmonary disease
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008103146A2 (en) * 2007-02-23 2008-08-28 Landing Biotech, Inc. Treating atherosclerosis
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
US8865179B2 (en) * 2008-01-26 2014-10-21 Swey-Shen Alexchen Aptameric IgE peptides in a protein scaffold as an allergy vaccine
CA2744754A1 (en) * 2008-12-09 2010-06-17 Pfizer Vaccines Llc Ige ch3 peptide vaccine
AU2013204233B2 (en) * 2008-12-09 2015-06-25 Pfizer Vaccines Llc IgE CH3 peptide vaccine
CN104548089B (zh) * 2009-09-03 2017-09-26 辉瑞疫苗有限责任公司 Pcsk9疫苗
CA2800774A1 (en) * 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
CN104395337A (zh) * 2012-06-18 2015-03-04 日本全药工业株式会社 IgE肽疫苗
CN104558196A (zh) * 2013-10-15 2015-04-29 温州医科大学 基于HBcAg载体的沙眼衣原体主要外膜蛋白表位疫苗及其用途
RU2745720C2 (ru) * 2014-07-25 2021-03-31 Юнайтед Байомедикал, Инк. Иммуногенная композиция lhrh и ее применение у свиней
WO2018037042A1 (en) * 2016-08-23 2018-03-01 Aimvion A/S Novel immunostimulating peptides
US12440557B2 (en) * 2017-12-31 2025-10-14 United Biomedical, Inc. Peptide immunogens and formulations thereof targeting membrane-bound IgE for treatment of IgE mediated allergic diseases
US10605226B2 (en) * 2018-08-14 2020-03-31 Lone Gull Holdings, Ltd. Inertial hydrodynamic pump and wave engine
EP4213874A1 (en) 2020-09-17 2023-07-26 Neovacs Immunogenic product comprising an ige fragment for treating ige-mediated inflammatory disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940782A (en) 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
EP0602126B1 (en) * 1991-08-14 2003-03-05 Genentech, Inc. Immunoglobulin variants for specific fc epsilon receptors
JP3795914B2 (ja) 1993-04-27 2006-07-12 ユナイテッド・バイオメディカル・インコーポレイテッド ワクチン用免疫原性ｌｈｒｈペプチド構築体および合成普遍免疫刺激器
EP0811016A1 (en) * 1994-03-28 1997-12-10 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
JPH09169795A (ja) 1995-12-22 1997-06-30 Hitachi Chem Co Ltd イヌ免疫グロブリンｅペプチド断片、それをコードするｄｎａ、そのｄｎａを含む組換えベクター、その組換えベクターを含む形質転換体及び抗イヌ免疫グロブリンｅ抗体の製造法
AU6532498A (en) 1996-12-06 1998-06-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Inhibition of ige-mediated allergies by a human ige-derived oligopeptide
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides

Also Published As

Publication number Publication date
CA2329754A1 (en) 1999-12-29
EP1090039B1 (en) 2009-04-22
JP4031201B2 (ja) 2008-01-09
JP2002518038A (ja) 2002-06-25
HK1036804A1 (en) 2002-01-18
BRPI9911389B8 (pt) 2021-05-25
TWI227241B (en) 2005-02-01
EP1090039A4 (en) 2002-08-07
CA2329754C (en) 2011-12-20
US6811782B1 (en) 2004-11-02
BRPI9911389B1 (pt) 2018-03-20
WO1999067293A1 (en) 1999-12-29
DK1090039T3 (da) 2009-07-27
AU4580299A (en) 2000-01-10
CN1259340C (zh) 2006-06-14
EP1090039A1 (en) 2001-04-11
AU757919B2 (en) 2003-03-13
DE69940775D1 (de) 2009-06-04
CN1305498A (zh) 2001-07-25
US7648701B2 (en) 2010-01-19
US20050250934A1 (en) 2005-11-10
ATE429448T1 (de) 2009-05-15
ZA200006384B (en) 2001-05-29

Similar Documents

Publication Publication Date Title
BR9911389A (pt) Composição de peptìdio como imunógeno para o tratamento de alergia
DE69941625D1 (de) Antigener komplex, der ein immunstimulierendes peptid enthält, cd4 und chemokinrezeptor-domäne zur behandlung von hiv und immunerkrankungen
BRPI0407058A (pt) Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
ATE244891T1 (de) Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
WO2003045128A3 (en) SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
CR8444A (es) Immunogenic peptide carrier conjugates and methods of producing same
CY1112639T1 (el) Ορθολογικως σχεδιασμενα αντισωματα
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
PT1326634E (pt) Composicao de vacina compreendendo um antigenio e um peptido possuindo propriedades adjuvantes
FI941757A0 (fi) Dermatofagoideista (talopölypunkki) peräisin olevien pääallergeenien T-soluepitoopit
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
NL300830I2 (nl) Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
ATE440860T1 (de) An proteinphosphatase 2a bindende synthetische oder natürliche peptide, identifikationsverfahren und anwendungen
DE69840509D1 (de) Apoptose-bezogene verbindungen und deren verwendung
ATE494301T1 (de) Alpha-fetoprotein-peptide und ihre verwendung
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DK0954529T3 (da) Porphyromonas gingivalis-antigener til diagnose og behandling af rodbetændelse
CA2363991A1 (en) Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor
Hudecz Manipulation of epitope function by modification of peptide structure: a minireview
ATE287952T1 (de) Humanes thymosin beta 15 gen,protein und dessen verwendungen
ATE336579T1 (de) Isolierte mhc-klasse ii-bindende peptide, und deren verwendung

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/03/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/06/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 21/06/2019